Lowest Price Guaranteed
Pages
80
Last Updated
July 2026
View Count
12411
Dashboard 1 is an interactive MS Excel dashboard that provides a detailed review of the contemporary developer landscape, featuring the identities and details of various innovator companies and their respective NK cell therapy candidates. The dashboard offers insights on current (highest) phase of development, source of NK cells (autologous and allogenic), target disease indication (hematological malignancies, solid tumors and others), type of therapy (monotherapy and combination therapy), route of administration and other relevant details (wherever available).
Dashboard 2 is an interactive MS Excel dashboard featuring an analysis of both completed and active clinical trials, which were registered starting from January 2009 to May 2019, featuring detailed charts on (primary) developer company (year of establishment, location of headquarters, and company size), type of developer (industry and non-industry), name of therapy, source of NK cells (autologous and allogenic), and other trial related details (collaborating sponsors, trial title, study objectives, location of trial, current status, availability of results, target therapeutic indication, study type, current / anticipated enrolment, study start / end date and key outcomes / results).
Dashboard 3 is another interactive MS Excel dashboard that offers a retrospective analysis of the various clinical development programs of NK cell based therapies clinical trials that have been discontinue for various reasons (highlighted wherever available). It is worth mentioning that in this analysis we have we have designated the “unknown” status to certain clinical development program that have not been updated from a long time, assuming that such trials are either terminated or indefinitely suspended. The analysis presented in this dashboard has been based on the identity and key details of developer company, (such as type of developer, geographical location), name of therapy, source of NK cells (autologous and allogenic), other trial related details (collaborating sponsors, trial title, study objectives, target therapeutic indication and study type) and reason for termination (wherever available).
1. Introduction and Scope
2. Developer Landscape
2A. Developer Landscape: Analysis by Location of Headquarters
2B. Developer Landscape: Analysis by Phase of Development
2C. Developer Landscape: Analysis by Target Disease Indication
2D. Developer Landscape: Analysis by Source of NK Cells
2E. Developer Landscape: Analysis by Type of Therapy
2F. Developer Landscape: Analysis by Route to Administration
2G. Developer Landscape: Analysis by Year of Establishment (Industry Players)
2H. Developer Landscape: Analysis by Company Size (Industry Players)
3. Completed and Active Trials
3A. Clinical Trial Analysis: Analysis by Current Trial Status
3B. Clinical Trial Analysis: Analysis by Phase of Development
3C. Clinical Trial Analysis: Analysis by Availability of Results
3D. Clinical Trial Analysis: Analysis by Target Disease Indication
3E. Clinical Trial Analysis: Analysis by Source of NK Cells
3F. Clinical Trial Analysis: Analysis by Type of Therapy
3G. Clinical Trial Analysis: Analysis by Study Type
3H. Clinical Trial Analysis: Analysis of Enrolled Patient Population
3I. Clinical Trial Analysis: Analysis by Study Start / End Dates
3J. Geographical Location of Primary Sponsor
3K. Geographical Location of Completed / Active Trials
4. Terminated Trials
4A. Terminated Trials: Analysis by Reason for Termination
4B. Terminated Trials: Analysis by Phase of Development
4C. Terminated Trials: Analysis by Target Disease Indication
4D. Terminated Trials: Analysis by Source of NK Cells
4E. Terminated Trials: Analysis by Type of Therapy
4F. Terminated Trials: Analysis by Study Type
5. Appendix I: Dataset 1: Developer Landscape
6. Appendix II: Dataset 2: Completed / Active Clinical Research Trials
7. Appendix III: Dataset 3: Terminated Clinical Research Trials
8. Appendix IV: Dataset 4: Clinical Research, 2009-2019
9. Abbreviations
10. Sources and Bibliography
Figure 2.1. Developer Landscape: Distribution by Location of Headquarters
Figure 2.2. Developer Landscape: Distribution by Phase of Development
Figure 2.3. Developer Landscape: Distribution by Target Disease Indication
Figure 2.4. Developer Landscape: Distribution by Source of NK Cells
Figure 2.5. Developer Landscape: Distribution by Type of Therapy
Figure 2.6. Developer Landscape: Distribution by Route to Administration
Figure 2.7. Developer Landscape: Distribution by Year of Establishment (Industry Players)
Figure 2.8. Developer Landscape: Distribution by Company Size (Industry Players)
Figure 3.1. Clinical Trial Analysis: Distribution by Current Trial Status
Figure 3.2. Clinical Trial Analysis: Distribution by Phase of Development
Figure 3.3. Clinical Trial Analysis: Distribution by Availability of Results
Figure 3.4. Clinical Trial Analysis: Distribution by Target Disease Indication
Figure 3.5. Clinical Trial Analysis: Distribution by Source of NK Cells
Figure 3.6. Clinical Trial Analysis: Distribution by Type of Therapy
Figure 3.7. Clinical Trial Analysis: Distribution by Study Type
Figure 3.7. Clinical Trial Analysis: Distribution of Enrolled Patient Population
Figure 3.7. Clinical Trial Analysis: Distribution by Study Start / End Dates
Figure 3.8. Geographical Location of Primary Sponsor
Figure 3.9. Geographical Location of Completed / Active Trials
Figure 4.1. Terminated Trials: Distribution by Reason for Termination
Figure 4.2. Terminated Trials: Distribution by Phase of Development
Figure 4.3. Terminated Trials: Distribution by Target Disease Indication
Figure 4.4. Terminated Trials: Distribution by Source of NK Cells
Figure 4.5. Terminated Trials: Distribution by Type of Therapy
Figure 4.6. Terminated Trials: Distribution by Study Type